Biotechnology

Biocytogen

Bioceanus Pharmaceutical Clarifies Shareholders' Meeting Circular Errors and Seeks Credit Facilities

Bioscience-B Plans to Invest 1.6 Billion in New Facilities

Biocytogen released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 433.06 M, actual EPS CNY 0.23

Biosettia Reports Scaled Profitability in 2025 Annual Report

Biocytogen FY2026 Q1 Earnings Release Scheduled for April 27 After-Market BJT

Biocytogen Announces 2025 Performance and License Agreement with Taisho Pharmaceutical

Innovative Drug Sector Benefits Baolisaite Bio's Earnings Report

Bioscience reported significant revenue and net profit growth in 2025 without dividend distribution

Biocytogen to Release FY2025 Earnings on March 26 After-Market (BJT), Forecast Revenue CNY 1.448 B

Biotium Announces Significant 2025 Earnings Growth and Promotes Licensing Collaborations

Biocytogen released FY2025 Q3 earnings on February 26, 2026 (BJT) with actual revenue of CNY 319.92 M and EPS of CNY 0.1669

Biocytogen released FY2025 9 Months Earnings on February 26, 2026 (BJT), with actual revenue of CNY 940.88 M and EPS of CNY 0.2881

Biocean Chart Announces Significant Revenue and Net Profit Growth in 2025

Biocytogen released FY2025 earnings on February 26 After-Market (BJT), actual revenue CNY 1.379 B (forecast CNY 1.448 B), actual EPS CNY 0.43

Biocytogen released FY2025 Q4 earnings on February 26 After-Market (BJT), actual revenue CNY 437.93 M, actual EPS CNY 0.1379

Biomabot Predicts Net Profit Increase of 384% to 444% in 2025

Bioscience-B and Yushibi Reach a Development Cooperation Agreement on Bispecific Antibody Drug Conjugate

Guolian Minsheng Securities First Coverage and Recommendation for Biocytogen

Biosceptre and Partner Ideaya Obtain FDA Approval to Advance IDE034 Phase I Clinical Trial for B7H3/PTK7 Bispecific Antibody Drug Conjugate

Biocytogen released FY2024 Semi-Annual Earnings on September 25 (BJT), actual revenue CNY 410.5 M (forecast CNY 410.21 M), actual EPS CNY -0.1272

688796

02315

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has clarified a clerical error in its AGM circular regarding a special resolution for credit facilities. The company plans to seek a consolidated bank credit line of up to RMB1.5 billion and provide guarantees for its subsidiaries' loans. This move aims to enhance financial flexibility and risk management, concentrating credit exposure at the group level. The company focuses on drug research and development and operates through its parent and subsidiaries, utilizing bank credit for funding needs.

Tip Ranks

BIOCYTOGEN-B

Biocytogen Clarifies AGM Resolution on RMB1.5 Billion Credit Facilities and Guarantees

Biocytogen Pharmaceuticals (Beijing) reported Q1 2026 revenue of ¥433.1 million and basic EPS of ¥0.23, reflecting significant year-over-year earnings growth and a net margin increase to 18.6% from 7.6%. The trailing twelve-month net income reached ¥290.5 million, supporting a bullish outlook despite concerns over profitability stability. The stock trades at HK$51.70 with a P/E of 69.3x, above industry averages, raising questions about valuation. Investors are encouraged to consider long-term trends and the company's growth potential amidst current market narratives.

Simplywall

Biocytogen Pharmaceuticals Beijing Q1 Margin Expansion Reinforces Bullish Earnings Narratives

516500

510660

512290

159102

588130

Biocytogen has partnered with Sihuan Pharmaceutical to develop new therapeutics, focusing on weight loss and other disease areas. The collaboration combines Biocytogen's human antibody discovery platform with Sihuan's drug development and commercialization expertise. This strategic alliance aims to accelerate the clinical and commercial progression of promising antibody therapeutics, leveraging advanced technologies and integrated platforms. Biocytogen's CEO, Dr. Yuelei Shen, expressed enthusiasm for the partnership, highlighting its potential to enhance their joint efforts in drug discovery and development.

Pharmaceutical Technology

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai CSI Bio-medicine ETF

China Universal 800 Health Care ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI 300 Health Care ETF

Huaan Hang Seng Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Guotai SSE STAR Brand Name Drug ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

Yinhua CSI Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Biocytogen and Sihuan partner to advance new therapeutics for weight loss

300497

300149

603538

301509

600721

CRO concept stocks fluctuated and strengthened, with Fushine and Menovo both hitting the daily limit, Kingchem rising more than 10%, and Biocytogen, BHC, and ChemPartner following suit

Wallstreetcn

Fushine

ChemPartner

Menovo

Kingchem

36Kr learned that Biocytogen released its performance forecast for 2025. The report shows that the net profit attributable to shareholders of the listed company is expected to be between 162 million yuan and 182 million yuan, a year-on-year increase of 384.26%-443.88%

36Kr

Biocytogen: Net profit is expected to increase by 384%-444% year-on-year in 2025

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has announced an extraordinary general meeting on February 12, 2026, to vote on the appointment of Mr. Liu Hongkang as a non-executive director. The meeting will be held in a hybrid format to enhance shareholder participation. This decision may influence the company's board composition and governance. The current analyst rating for Biocytogen's stock (HK:2315) is a Hold, with a price target of HK$48.00 and a market cap of HK$16.99B.

Biocytogen Calls 2026 Extraordinary Meeting to Vote on New Non-Executive Director